CD28/CTLA-4 ligands: the gene encoding CD86 (B70/B7.2) maps to the same region as CD80 (B7/B7.1) gene in human chromosome 3q13-q23

European Journal of Immunology
E Fernández-RuizL L Lanier

Abstract

CD86 (B70/B7.2) is an antigen of the immunoglobulin superfamily expressed on monocytes, dendritic cells and activated B, T, and natural killer cells. CD86 was recently identified as a second ligand for the T cell antigens CD28 and CTLA-4, and plays an important role in the co-stimulation of T cells in a primary immune response. We report here the assignment of the CD86 gene to human chromosome 3 using Southern blot analysis on a panel of hamster x human somatic cell hybrid genomic DNA. Fluorescence hybridization in situ on metaphase chromosomes coupled with GTG banding (G-bands by trypsin using Giemsa staining) confirmed this assignment and localized the CD86 gene to 3q13-q23 region. The CD86 gene is, therefore, located in the proximity of the CD80 (B7/B7.1) gene, the first identified ligand for CD28 and CTLA-4, previously mapped to chromosome 3q13.3-q21. Deletions, inversions and insertions of chromosome 3q21-q26, as well as translocations of 3q21 with other chromosomes have been described in many cases of acute myeloid leukemia (AML), acute non-lymphocytic leukemia (ANLL), chronic myeloid leukemia (CML) and myelodisplastic syndromes (MDS), suggesting that this region contains several genes involved in the leukemic process.

References

Feb 1, 1992·European Journal of Immunology·E Fernández-RuizF Sánchez-Madrid
Sep 1, 1991·The Journal of Experimental Medicine·P S LinsleyJ A Ledbetter
Jul 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·P S LinsleyJ A Ledbetter
Jul 1, 1994·Immunology Today·C H JuneC B Thompson
Jun 1, 1994·Current Opinion in Immunology·J P Allison
Nov 4, 1993·Nature·M AzumaC Somoza
Jan 1, 1993·Annual Review of Immunology·P S Linsley, J A Ledbetter
Jan 1, 1993·Cytogenetics and Cell Genetics·E Fernández-RuizC Bernabéu

❮ Previous
Next ❯

Citations

Jul 10, 2003·Cancer Genetics and Cytogenetics·Donna O McCarthyMark R Albertini
Dec 1, 1996·Current Opinion in Immunology·E A TivolA H Sharpe
Jul 21, 2010·Journal of Autoimmunity·Efstathia K Kapsogeorgou, Menelaos N Manoussakis
Apr 2, 2010·Journal of Reproductive Immunology·Ayesha ShakhawatNelson Fernández
Oct 1, 1996·Immunological Reviews·P WaterhouseT W Mak
Jun 19, 2019·Experimental Biology and Medicine·Sean M West, Xiaodi A Deng
Oct 16, 2019·Asia-Pacific Journal of Clinical Oncology·Youchun ChenShaohua Chen
Aug 9, 2002·The Journal of Biological Chemistry·Sasha LazeticJuha Punnonen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Cancer Biology: Molecular Imaging

Molecular imaging enables noninvasive imaging of key molecules that are crucial to tumor biology. Discover the latest research in molecular imaging in cancer biology in this feed.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.